JNJ-26489112

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
JNJ-26489112
Accession Number
DB15203
Description

JNJ-26489112 is under investigation in clinical trial NCT00579384 (A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 278.71
Monoisotopic: 278.0128057
Chemical Formula
C9H11ClN2O4S
Synonyms
Not Available

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with JNJ-26489112.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with JNJ-26489112.
AclidiniumJNJ-26489112 may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with JNJ-26489112.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with JNJ-26489112.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with JNJ-26489112.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with JNJ-26489112.
AlosetronThe risk or severity of adverse effects can be increased when Alosetron is combined with JNJ-26489112.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with JNJ-26489112.
AlverineThe risk or severity of adverse effects can be increased when Alverine is combined with JNJ-26489112.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
G1TI012DLT
CAS number
871824-55-4
InChI Key
KXSAIQPPGSSNKX-ZETCQYMHSA-N
InChI
InChI=1S/C9H11ClN2O4S/c10-6-1-2-8-9(3-6)15-5-7(16-8)4-12-17(11,13)14/h1-3,7,12H,4-5H2,(H2,11,13,14)/t7-/m0/s1
IUPAC Name
N-{[(2S)-6-chloro-2,3-dihydro-1,4-benzodioxin-2-yl]methyl}aminosulfonamide
SMILES
NS(=O)(=O)NC[C@H]1COC2=C(O1)C=CC(Cl)=C2

References

General References
Not Available
ChemSpider
9790860
BindingDB
50444089
ChEMBL
CHEMBL3092995
Wikipedia
JNJ-26489112

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentPhotosensitive Epilepsy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.9 mg/mLALOGPS
logP1.31ALOGPS
logP0.21ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)10.21ChemAxon
pKa (Strongest Basic)0.23ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area90.65 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity61.26 m3·mol-1ChemAxon
Polarizability25.58 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on May 20, 2019 08:59 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates